Clinical trial · Observational
Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
Observational Prospective Study of Survival, Treatment Patterns, Disease and Economic Outcomes in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Progression During or After a First-line Docetaxel-based Regimen
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): delay in recruitment
Summary
Brief summary (as posted)
Primary Objective: * Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression Secondary Objective: * Describe treatment patterns * Describe the characteristics and outcomes of patients who received second-line taxane-based treatment compared to others * Describe economic and patient-reported outcomes
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- CRPC patients
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- At Month 12 or death
Secondary outcomes (4)
- measure
- Sequence of treatment in second-line, third-line
- timeFrame
- At Month 6 (+/- 2 months), Month 12 or death
- measure
- Characteristics and outcomes of patients who receive second-line taxane-based treatment compared to others
- timeFrame
- At baseline, Month 6 (+/- 2 months), Month 12 or death
- measure
- Indicators of health care resource utilization
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion criteria: * Patients with CRPC progressing during the course of first line docetaxel-based chemotherapy or after at least 3 cycles (equivalent to 225mg/m2) of first line docetaxel-based chemotherapy * Patient who have given their written consent Exclusion criteria: * Current participation in a clinical trial for the second-line treatment of prostate cancer * Patients having received less than 3 cycles of first line docetaxel-based chemotherapy and discontinued for a reason other than disease progression or toxicity * Patients having already started a second line treatment The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
References
Publications (0)
Data not yet available